載入中
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
前收盤價
US$2.51
+US$0.14 · +5.91%
盤中時間採用ET。市場資料可能有所延遲。
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
日內區間
目前US$2.51
52週區間
目前US$2.51
盤中時間採用ET。市場資料可能有所延遲。
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
日內區間
目前US$2.51
52週區間
目前US$2.51
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 934.1萬 USD | 725.11萬 USD | 762.17萬 USD | 632.47萬 USD | 252.32萬 USD |
| 銷售、一般及管理費用 | 1049.26萬 USD | 811.47萬 USD | 875.68萬 USD | 858.62萬 USD | 520.6萬 USD |
| 營業費用 | 1983.35萬 USD | 1536.58萬 USD | 1637.85萬 USD | 1491.09萬 USD | 772.91萬 USD |
| 利息收入 | — | — | — | 58.81萬 USD | 1.77萬 USD |
| 折舊和攤銷 | — | 735 USD | 1284 USD | 1781 USD | 1403 USD |
| 營業利益 | −1983.35萬 USD | −1536.58萬 USD | −1637.85萬 USD | −1491.09萬 USD | −772.91萬 USD |
| 淨利 | −2084.89萬 USD | −1502.2萬 USD | −1542.35萬 USD | −1432.28萬 USD | −771.14萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年6月27日 | 1:28 | — | — |
股票分割 | 2021年7月27日 | 1:4 | — | — |
股票分割 | 2020年10月30日 | 1:20 | — | — |
已生效 2025年6月27日
1:28
已生效 2021年7月27日
1:4
已生效 2020年10月30日
1:20
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
